Posted on by

The Luna TMVR system achieves implantations in humans for the first time

The Luna TMVR system achieves implantations in humans for the first time

The implantations were carried out by doctors from Paraguay and the Republic of Georgia together with a team of US doctors. Photo credit: Tioga Cardiovascular. Inc/ PR Newswire.

Medical device company Tioga Cardiovascular has achieved its first human transseptal implantations with the 28-Fr. Luna transcatheter mitral valve replacement system (TMVR).

It is claimed that the procedures resulted in “excellent” haemodynamics in the first few patients following surgery.

The cases were conducted in Paraguay and the Republic of Georgia. These were carried out by doctors Adrian Ebner from Asuncion, Paraguay; and Irakli Gogorishvili of Tbilisi, Republic of Georgia, along with assistance from a team of U.S. physicians.

Mitral valve interventions present significant challenges due to the anatomical and functional complexity of the mitral valve.

These complexities include proximity to the left ventricular outflow tract (LVOT) and large ring sizes.

Therefore, developing effective and safe transcatheter TMVR solutions has been a major challenge.

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company profile – free sample

Your download email will arrive shortly

We are convinced of the unique quality of our company profiles. However, because we want you to make the most beneficial decision for your business, we offer you a free sample that you can download by filling out the form below

By GlobalData







Visit our Privacy Policy for more information about our Services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can opt-out of future marketing communications. Our Services are intended for corporate subscribers and you warrant that the email address provided is your corporate email address.

According to Dr. According to Dr. Latib of Montefiore Medical Center, New York, the Luna TMVR system is designed to address many of these challenges.

Mike Dineen, President and CEO of Tioga Cardiovascular, said, “This is an exciting milestone for Tioga and we look forward to additional clinical cases with our Luna TMVR System.”

“I would like to thank our clinical researchers and their teams for their commitment to clinical excellence in the first cases of the Luna System. We look forward to sharing more details about the Luna TMVR system at TCT next week.”

The Luna TMVR System will be presented during the “Innovations in Transcatheter Mitral Valve Replacement Technologies” session at the upcoming Transcatheter Cardiocular Therapeutics (TCT) conference.

The event is scheduled for October 29 in Washington, DC.